For evaluating and predicting the efficacy of nCRT, various studies have used morphological features represented by TNM stage and tumor regression grade (TRG)[3], tumor marker features represented by carcinoembryonic antigen (CEA) and carbohydrate antigen-199 (CA199) levels [4, 5], and tumor microenvironment-related molecular features, such as EGFR, VEGF, and Ki67 [6, 7]. This evidence concerns the gene CEACAM5 and neoplasm.